Related Experiment Videos
Quantifying adverse drug events : are systematic reviews the answer?
Mahyar Etminan1, Bruce Carleton, Paula A Rochon
1Division of Clinical Epidemiology, Royal Victoria Hospital, Montreal, Canada. metminan@shaw.ca
Drug Safety
|September 8, 2004
Summary
Quantifying adverse drug events (ADEs) is crucial for healthcare. Challenges in reporting and indexing ADEs hinder systematic reviews, impacting clinical decision-making and patient safety.
Area of Science:
- Pharmacovigilance
- Clinical Trial Methodology
- Evidence Synthesis
Background:
- Adverse drug events (ADEs) quantification is vital for clinicians, consumers, and policymakers.
- Clinical trials are a primary source of ADE data, but systematic reviews face significant challenges.
- Systematic reviews are valuable for assessing therapeutic efficacy and drug risks.
Purpose of the Study:
- To discuss the challenges faced by clinicians conducting systematic reviews of ADEs.
- To identify key areas hindering the effective use of ADE data from clinical trials.
- To explore potential strategies for overcoming these obstacles.
Main Methods:
- Literature review and analysis of ADE reporting in randomized trials.
- Examination of medical database indexing practices for ADEs.
- Illustrative examples from existing research to highlight challenges.
Main Results:
- Two primary challenges identified: poor quality of ADE reporting in randomized trials and inadequate indexing of ADEs in medical databases.
- Examples demonstrate the difficulties in extracting and synthesizing reliable ADE data.
- Potential strategies for improvement are discussed.
Conclusions:
- Improving ADE reporting standards in clinical trials is essential.
- Enhanced indexing of ADE terminology in medical databases is necessary.
- Addressing these issues will strengthen systematic reviews of ADEs, benefiting clinical practice.